AAPL   382.54 (-0.30%)
FB   239.44 (-2.30%)
GOOGL   1,549.94 (+0.71%)
AMZN   3,100.65 (-3.10%)
NVDA   401.82 (-4.14%)
CGC   17.33 (-0.52%)
BABA   251.08 (-3.80%)
MU   50.70 (+0.00%)
GE   6.71 (+0.30%)
TSLA   1,497.00 (-3.08%)
AMD   53.63 (-4.03%)
GILD   76.72 (+0.52%)
BAC   24.18 (+0.67%)
BA   175.63 (-1.57%)
AAPL   382.54 (-0.30%)
FB   239.44 (-2.30%)
GOOGL   1,549.94 (+0.71%)
AMZN   3,100.65 (-3.10%)
NVDA   401.82 (-4.14%)
CGC   17.33 (-0.52%)
BABA   251.08 (-3.80%)
MU   50.70 (+0.00%)
GE   6.71 (+0.30%)
TSLA   1,497.00 (-3.08%)
AMD   53.63 (-4.03%)
GILD   76.72 (+0.52%)
BAC   24.18 (+0.67%)
BA   175.63 (-1.57%)
AAPL   382.54 (-0.30%)
FB   239.44 (-2.30%)
GOOGL   1,549.94 (+0.71%)
AMZN   3,100.65 (-3.10%)
NVDA   401.82 (-4.14%)
CGC   17.33 (-0.52%)
BABA   251.08 (-3.80%)
MU   50.70 (+0.00%)
GE   6.71 (+0.30%)
TSLA   1,497.00 (-3.08%)
AMD   53.63 (-4.03%)
GILD   76.72 (+0.52%)
BAC   24.18 (+0.67%)
BA   175.63 (-1.57%)
AAPL   382.54 (-0.30%)
FB   239.44 (-2.30%)
GOOGL   1,549.94 (+0.71%)
AMZN   3,100.65 (-3.10%)
NVDA   401.82 (-4.14%)
CGC   17.33 (-0.52%)
BABA   251.08 (-3.80%)
MU   50.70 (+0.00%)
GE   6.71 (+0.30%)
TSLA   1,497.00 (-3.08%)
AMD   53.63 (-4.03%)
GILD   76.72 (+0.52%)
BAC   24.18 (+0.67%)
BA   175.63 (-1.57%)
Log in

NASDAQ:EIDXEidos Therapeutics Stock Price, Forecast & News

$48.25
-0.57 (-1.17 %)
(As of 07/13/2020 03:55 PM ET)
Add
Compare
Today's Range
$47.65
Now: $48.25
$49.87
50-Day Range
$43.70
MA: $48.06
$52.04
52-Week Range
$28.00
Now: $48.25
$66.56
Volume42,800 shs
Average Volume98,767 shs
Market Capitalization$1.86 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.27
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California.
Read More
Eidos Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.14 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EIDX
CUSIPN/A
CIKN/A
Phone415-887-1471

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.69 million
Book Value$4.57 per share

Profitability

Net Income$-37,830,000.00

Miscellaneous

Employees28
Market Cap$1.86 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableNot Optionable

Receive EIDX News and Ratings via Email

Sign-up to receive the latest news and ratings for EIDX and its competitors with MarketBeat's FREE daily newsletter.

Eidos Therapeutics (NASDAQ:EIDX) Frequently Asked Questions

How has Eidos Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Eidos Therapeutics' stock was trading at $43.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EIDX shares have increased by 10.0% and is now trading at $48.27. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Eidos Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eidos Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eidos Therapeutics.

When is Eidos Therapeutics' next earnings date?

Eidos Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Eidos Therapeutics.

How were Eidos Therapeutics' earnings last quarter?

Eidos Therapeutics Inc (NASDAQ:EIDX) announced its earnings results on Friday, May, 8th. The company reported ($0.60) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $0.07. View Eidos Therapeutics' earnings history.

What price target have analysts set for EIDX?

10 analysts have issued 1-year target prices for Eidos Therapeutics' shares. Their forecasts range from $34.00 to $80.00. On average, they expect Eidos Therapeutics' stock price to reach $57.80 in the next twelve months. This suggests a possible upside of 19.7% from the stock's current price. View analysts' price targets for Eidos Therapeutics.

Has Eidos Therapeutics been receiving favorable news coverage?

Media stories about EIDX stock have been trending very negative this week, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eidos Therapeutics earned a news impact score of -3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Eidos Therapeutics.

Who are some of Eidos Therapeutics' key competitors?

What other stocks do shareholders of Eidos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eidos Therapeutics investors own include Crispr Therapeutics (CRSP), Exelixis (EXEL), Micron Technology (MU), Aduro BioTech (ADRO), Agile Therapeutics (AGRX), ImmunoGen (IMGN), Pfizer (PFE), Roku (ROKU), Sangamo Therapeutics (SGMO) and Clovis Oncology (CLVS).

Who are Eidos Therapeutics' key executives?

Eidos Therapeutics' management team includes the following people:
  • Dr. Neil Kumar, CEO & Director (Age 40)
  • Dr. Isabella Graef M.D., Founder & Board Advisor (Age 54)
  • Dr. Uma Sinha, Chief Scientific Officer (Age 62)
  • Dr. Cameron Turtle, Chief Bus. Officer (Age 29)
  • Dr. Hoyoung Huh, Consultant (Age 50)

When did Eidos Therapeutics IPO?

(EIDX) raised $101 million in an initial public offering (IPO) on Wednesday, June 20th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Barclays was co-manager.

What is Eidos Therapeutics' stock symbol?

Eidos Therapeutics trades on the NASDAQ under the ticker symbol "EIDX."

How do I buy shares of Eidos Therapeutics?

Shares of EIDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eidos Therapeutics' stock price today?

One share of EIDX stock can currently be purchased for approximately $48.27.

How big of a company is Eidos Therapeutics?

Eidos Therapeutics has a market capitalization of $1.86 billion and generates $26.69 million in revenue each year. The company earns $-37,830,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Eidos Therapeutics employs 28 workers across the globe.

What is Eidos Therapeutics' official website?

The official website for Eidos Therapeutics is www.eidostx.com.

How can I contact Eidos Therapeutics?

Eidos Therapeutics' mailing address is 101 MONTGOMERY STREET SUITE 2000, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-887-1471 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.